1. Dexamethasone intravitreal implant in cystoid macular edema secondary to paclitaxel therapy
- Author
-
Barbara Burgos-Blasco, Samuel Hernandez-Ruiz, Lorenzo Lopez-Guajardo, and Juan Donate-Lopez
- Subjects
Cystoid macular edema ,Paclitaxel ,Intravitreal dexamethasone implant ,Ophthalmology ,RE1-994 - Abstract
Purpose: To report the first case of cystoid macular edema (CME) induced by nabpaclitaxel treated with intravitreal dexamethasone implant. Observations: A 67 year-old man diagnosed with unresectable pancreatic cancer presented with decreased vision in both eyes while receiving nab-paclitaxel. He was diagnosed with CME and intravitreal dexamethasone implants were administered in both eyes. Central retinal thickness (CRT) of both eye decreased 1 month after the implant but CME persisted. 2 months after Ozurdex implant nabpaclitaxel was discontinued, improving central macular thickness and the CME significantly in both eyes. Conclusion and importance: Cessation of nab-paclitaxel could lead to resolution of CME more than intravitreal dexamethasone implant, although intravitreal dexamethasone implant achieved some reduction in central macular thickness.
- Published
- 2020
- Full Text
- View/download PDF